[Laparoscopic conservative surgery plus gonadotropin-releasing hormone agonist in the treatment of endometriosis: a meta-analysis].
article
OA: closed
CC0
AI-generated summary
Laparoscopic conservative surgery plus GnRH-a decreased pain recurrence in endometriosis patients but did not improve pregnancy rates compared to surgery alone.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
OBJECTIVE: To evaluate the efficacy of laparoscopic conservative surgery plus gonadotropin-releasing hormone agonist (GnRH-a) in the treatment of endometriosis through meta-analysis. METHODS: Six randomized controlled clinical trials comparing laparoscopic conservative surgery plus GnRH-a versus placebo or no treatment for endometriosis were retrieved. Meta-analysis was conducted to estimate the efficacy. RESULTS: A total of 477 patients were included. Among them, 233 patients received laparoscopic conservative surgery plus GnRH-a while another 244 laparoscopic surgery alone. The results of meta-analysis showed that laparoscopic conservative surgery plus GnRH-a could decrease the recurrence of pain symptoms (P 0.05). Furthermore the combined regiment could better improve clinical symptoms than placebo. CONCLUSION: Laparoscopic conservative surgery plus GnRH-a could decrease the recurrence of pain symptoms associated with endometriosis, but it failed to increase the pregnancy rate of infertility.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.
Source provenance
- europepmc
- last seen: 2026-06-04T01:30:01.192114+00:00
- openalex
- last seen: 2026-06-04T00:00:01.174412+00:00
- pubmed
- last seen: 2026-05-13T22:18:40.923139+00:00
License: CC0
· commercial use OK